Product Information
ENOXAPARIN 40 MG/0.4 ML SYR is a generic product labeled by Sanofi-Aventis U.S. LLC, priced at $7.7791 per ML under NDC 00955100410. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 29, 1993. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the enoxaparin sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/.4mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00955100410
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ENOXAPARIN SODIUMApproval Type
Authorized Generic (NDA)
FDA Application
NDA020164FDA Approved
3/29/1993
TE Code
AP
On Market Since
10/3/2011
Pharmacological Classes
Price Statistics
The NADAC for ENOXAPARIN 40 MG/0.4 ML SYR has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 79.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.7791 per ML |
|---|---|
| All-time high | $40.2380 (Jan 15, 2014) |
| All-time low | $7.7791 (Sep 23, 2026) |
| 52-week high | $9.2335 |
| 52-week low | $7.7791 |
| Median price | $12.4050 |
| Average price | $14.8454 |
| Largest weekly change | -25.0% (Aug 19, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
enoxaparin sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Low Molecular Weight Heparin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENOXAPARIN 40 MG/0.4 ML SYR?
The current National Average Drug Acquisition Cost (NADAC) for ENOXAPARIN 40 MG/0.4 ML SYR, manufactured by Sanofi-Aventis U.S. LLC, is $7.7791 per ML (NDC 00955100410), effective Sep 30, 2026.
How has the price of ENOXAPARIN 40 MG/0.4 ML SYR changed over time?
Over the history we have for it, the NADAC for ENOXAPARIN 40 MG/0.4 ML SYR has declined 79.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ENOXAPARIN 40 MG/0.4 ML SYR?
Since Nov 28, 2013, the NADAC for ENOXAPARIN 40 MG/0.4 ML SYR has ranged from a low of $7.7791 (Sep 23, 2026) to a high of $40.2380 (Jan 15, 2014), with a median of $12.4050 per ML.
Are there cheaper alternatives to ENOXAPARIN 40 MG/0.4 ML SYR?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LOVENOX 40 MG/0.4 ML SYRINGE, is $6.7750 per ML — about 13% below ENOXAPARIN 40 MG/0.4 ML SYR.
Who manufactures ENOXAPARIN 40 MG/0.4 ML SYR?
ENOXAPARIN 40 MG/0.4 ML SYR (NDC 00955100410) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a generic product.